Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niels Vrang

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
World Journal of Gastroenterology|January 30, 2018
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitisKirstine S Tølbøl, Maria Nb Kristiansen, Henrik H Hansen, et al.
Plos One|July 16, 2016
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's DiseaseHenrik H Hansen, Katrine Fabricius, Pernille Barkholt, et al.
Journal of Alzheimer'S Disease : JAD|April 15, 2015
The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's DiseaseHenrik H Hansen, Katrine Fabricius, Pernille Barkholt, et al.
Kidney360|April 4, 2022
Automated Image Analyses of Glomerular Hypertrophy in a Mouse Model of Diabetic NephropathyMette V Østergaard, Frederikke E Sembach, Jacob L Skytte, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|October 24, 2017
GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic miceSøren B van Witteloostuijn, Louise S Dalbøge, Gitte Hansen, et al.
The European Journal of Neuroscience|April 27, 2021
Whole-brain mapping of amylin-induced neuronal activity in receptor activity-modifying protein 1/3 knockout miceGrethe Skovbjerg, Urmas Roostalu, Henrik H Hansen, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|December 19, 2014
Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intakeLouise S Dalbøge, Søren L Pedersen, Søren B van Witteloostuijn, et al.
Neuroinformatics|October 16, 2020
An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence MicroscopyJohanna Perens, Casper Gravesen Salinas, Jacob Lercke Skytte, et al.
American Journal of Physiology. Renal Physiology|June 28, 2021
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney diseaseMette V Østergaard, Thomas Secher, Michael Christensen, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|August 7, 2012
Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-helix variants of PYY3-36Søren L Pedersen, Vikram K Bhatia, Simon Jurt, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
World Journal of Gastroenterology|January 30, 2018
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitisKirstine S Tølbøl, Maria Nb Kristiansen, Henrik H Hansen, et al.
Plos One|July 16, 2016
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's DiseaseHenrik H Hansen, Katrine Fabricius, Pernille Barkholt, et al.
Journal of Alzheimer'S Disease : JAD|April 15, 2015
The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's DiseaseHenrik H Hansen, Katrine Fabricius, Pernille Barkholt, et al.
Kidney360|April 4, 2022
Automated Image Analyses of Glomerular Hypertrophy in a Mouse Model of Diabetic NephropathyMette V Østergaard, Frederikke E Sembach, Jacob L Skytte, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|October 24, 2017
GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic miceSøren B van Witteloostuijn, Louise S Dalbøge, Gitte Hansen, et al.
The European Journal of Neuroscience|April 27, 2021
Whole-brain mapping of amylin-induced neuronal activity in receptor activity-modifying protein 1/3 knockout miceGrethe Skovbjerg, Urmas Roostalu, Henrik H Hansen, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|December 19, 2014
Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intakeLouise S Dalbøge, Søren L Pedersen, Søren B van Witteloostuijn, et al.
Neuroinformatics|October 16, 2020
An Optimized Mouse Brain Atlas for Automated Mapping and Quantification of Neuronal Activity Using iDISCO+ and Light Sheet Fluorescence MicroscopyJohanna Perens, Casper Gravesen Salinas, Jacob Lercke Skytte, et al.
American Journal of Physiology. Renal Physiology|June 28, 2021
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney diseaseMette V Østergaard, Thomas Secher, Michael Christensen, et al.
Journal of Peptide Science : an Official Publication of the European Peptide Society|August 7, 2012
Improving membrane binding as a design strategy for amphipathic peptide hormones: 2-helix variants of PYY3-36Søren L Pedersen, Vikram K Bhatia, Simon Jurt, et al.
Pageof 10